STOCK TITAN

Gain Therapeutics, Inc. - GANX STOCK NEWS

Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.

Gain Therapeutics, Inc. (NASDAQ: GANX) is a pioneering biotechnology company committed to the discovery and development of novel small molecule therapeutics. Specializing in addressing rare genetic diseases, Gain Therapeutics focuses on orphan diseases caused by inborn errors of metabolism. With a strong emphasis on lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology, the company's innovative approach aims to provide solutions where there is a high unmet medical need.

At the forefront of Gain Therapeutics' pipeline is GT-02287, a promising clinical-stage product candidate targeting GBA1 Parkinson's disease. Currently in Phase 1 clinical trials, GT-02287 is designed to be a disease-modifying treatment. It functions as an allosteric protein modulator to restore the activity of the lysosomal enzyme glucocerebrosidase (GCase), tackling the underlying cause of disease rather than just alleviating symptoms.

The company's proprietary Magellan™ platform leverages AI-supported structural biology and advanced algorithms to discover novel allosteric binding sites on disease-implicated proteins. This innovative computational technology identifies potential small molecules that can bind to these sites, offering new avenues for therapeutic development. Magellan builds upon Gain’s original SEE-Tx® platform, enhancing it with AI and virtual screening capabilities to explore vast chemical spaces.

Recent achievements highlight Gain Therapeutics' impact on the biotech landscape. Data presented at the 20th WORLDSymposium™ showcased the progressive reversal of motor deficits in preclinical models, alongside a significant reduction of neurodegeneration biomarkers. This underscores the potential of GT-02287 as a best-in-class treatment for neurodegenerative diseases.

Gain Therapeutics collaborates with notable organizations including The Michael J. Fox Foundation for Parkinson’s Research and The Silverstein Foundation for Parkinson’s with GBA. These partnerships provide essential support and validation for the company's mission to transform therapeutic landscapes with innovative treatments.

For more information, visit GainTherapeutics.com and follow their updates on LinkedIn.

Rhea-AI Summary

Gain Therapeutics announced the completion of dosing in the Multiple Ascending Dose (MAD) part of their Phase 1 study for GT-02287, a novel small molecule therapy for Parkinson's Disease. Conducted without any serious adverse events or discontinuations, the study indicates that GT-02287 is well-tolerated. The topline data from this randomized, double-blind, placebo-controlled study is expected in mid-August 2024, with full safety analysis and plasma pharmacokinetics to be presented later. The company aims to initiate trials in Parkinson’s disease patients by Q4 2024. The MAD phase, begun in February 2024, involved 32 healthy volunteers completing 14 days of daily oral doses. The completion of the Single Ascending Dose (SAD) part in April 2024 also reported no serious adverse events. Preclinical data shows GT-02287 effectively restores the function of the enzyme glucocerebrosidase, which is linked to Parkinson’s disease due to GBA1 gene mutations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.36%
Tags
-
Rhea-AI Summary

Gain Therapeutics (Nasdaq: GANX) has announced a business update conference call scheduled for July 1, 2024, at 8:30am ET, hosted by interim-CEO and current CFO Gene Mack. This call will provide a corporate update and can be accessed via the company's website. A recorded version and transcript will be available on the site within 24 hours post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.5%
Tags
conference call
-
Rhea-AI Summary

Gain Therapeutics (NASDAQ: GANX) has announced the appointment of Gene Mack as interim CEO following the departure of Matthias Alder, effective June 25, 2024. Mack will also retain his role as CFO. Khalid Islam, founder and Chairman, will serve as Executive Chairman during the transition. Alder contributed significantly to the company's progress, particularly advancing GT-02287 into clinical development, which recently showed promising preclinical results for improving cognitive performance in GBA1 Parkinson's disease models. The company remains focused on the continued development of GT-02287.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
management
Rhea-AI Summary

Gain Therapeutics has presented data at the Federation of European Neuroscience Societies (FENS) Forum 2024 showing that their lead therapeutic candidate, GT-02287, has significantly improved cognitive function and activities of daily living in a preclinical model of GBA1 Parkinson's disease (GBA1-PD). The study demonstrated a reversal of motor function deficits in mice, assessed through nest-building and motor performance tests. The GT-02287 therapy was administered orally and showed promising results in enhancing daily activities reflecting human cognitive performance. The presentation, made on June 27, 2024, aligns with the company’s ongoing Phase 1 clinical study aimed at delivering effective treatments for Parkinson’s disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
none
-
Rhea-AI Summary

Gain Therapeutics, a clinical-stage biotechnology company, announced that its CFO, Gene Mack, will participate in H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024. The event will feature a fireside chat and virtual one-on-one meetings. Attendees can watch the fireside chat starting at 7:00am ET through an on-demand webcast. A replay will be available on Gain Therapeutics' website under the Investors and Media section following the event. Gain Therapeutics is recognized for its work in developing allosteric small molecule therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
conferences
-
Rhea-AI Summary

Gain Therapeutics announced the pricing of an $11.0 million public offering, consisting of 7,116,547 common shares at $1.35 per share and pre-funded warrants for 1,031,602 shares. The pre-funded warrants are exercisable immediately. Gain has also given the underwriter a 30-day option to purchase an additional 1,222,222 common shares. Titan Partners Group is the sole bookrunner. The offering is set to close around June 17, 2024, pending customary conditions. The proceeds will support clinical and nonclinical development of GT-02287 for neurodegenerative diseases and other corporate purposes. The securities are being offered via a prospectus supplement, which is available on the SEC's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.39%
Tags
Rhea-AI Summary

Gain Therapeutics, a Nasdaq-listed company (GANX), announced a public offering of its common stock and pre-funded warrants. The offering's final terms will depend on market conditions. Gain plans to use the proceeds to further develop its lead candidate, GT-02287, aimed at treating neurodegenerative diseases like GBA1 Parkinson's disease, and for general corporate purposes. Titan Partners Group is the sole bookrunner for this offering. All securities will be offered by Gain under a previously filed shelf registration statement with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.39%
Tags
-
Rhea-AI Summary

Gain Therapeutics has announced that its late-breaking abstract on GT-02287, a clinical-stage GCase enhancer, has been accepted for presentation at the FENS Forum 2024 in Vienna. New data reveals improvements in cognitive performance in a preclinical model of GBA1 Parkinson’s disease. The presentation is scheduled for June 27, 2024, and will be delivered by Dr. Beatriz Calvo-Flores Guzman. The FENS Forum is Europe's largest neuroscience congress, encompassing both basic and translational research. This recognition could potentially highlight the innovative strides Gain Therapeutics is making in the biotechnology sector, particularly in treating neurodegenerative diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.46%
Tags
none
-
Rhea-AI Summary

Gain Therapeutics (Nasdaq: GANX) has released its Q1 2024 financial results, reporting positive developments despite a decrease in both R&D and G&A expenses. The company announced favorable outcomes from the SAD part of its Phase 1 GT-02287 trial, initiated the MAD portion, and presented promising data on neuroprotection in Parkinson’s models.

Key executive appointments were made, with Gene Mack as CFO and Jonas Hannestad as CMO. The company maintains a cash runway into 2025, supported by potential grant applications. Financially, R&D expenses decreased by $0.3M to $2.5M, and G&A expenses fell by $0.6M to $1.9M. Net loss per share improved to $0.22 from $0.43 YoY. Cash reserves dropped to $12.7M from $16.8M year-end 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
Rhea-AI Summary
Gain Therapeutics announces positive results from the single ascending dose (SAD) part of the Phase 1 Clinical Trial of GT-02287, a novel GCase-targeting small molecule therapy for GBA1 Parkinson’s Disease. The trial showed GT-02287 was well tolerated with no serious adverse events, achieving appropriate plasma exposure levels. GT-02287 aims to slow or stop Parkinson's disease progression by treating the underlying cause. Preclinical data also showed promising results in restoring motor function and reducing neurodegeneration biomarkers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.9%
Tags

FAQ

What is Gain Therapeutics, Inc.?

Gain Therapeutics, Inc. is a biotechnology company focused on discovering and developing novel small molecule therapeutics for rare genetic diseases and other serious conditions.

What diseases is Gain Therapeutics targeting?

The company targets lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology, with a focus on GBA1 Parkinson's disease.

What is GT-02287?

GT-02287 is a clinical-stage product candidate being developed by Gain Therapeutics for the treatment of GBA1 Parkinson's disease. It aims to restore the function of the enzyme glucocerebrosidase (GCase).

How does Gain Therapeutics discover new treatments?

The company uses its proprietary Magellan™ platform, which combines AI-supported structural biology and advanced algorithms to identify novel allosteric binding sites on proteins.

What recent achievements has Gain Therapeutics made?

Recent data presented at the 20th WORLDSymposium™ showed the potential of GT-02287 to reverse motor deficits and reduce neurodegeneration biomarkers in preclinical models.

Who are Gain Therapeutics' partners?

Gain Therapeutics collaborates with organizations such as The Michael J. Fox Foundation for Parkinson’s Research and The Silverstein Foundation for Parkinson’s with GBA.

What is the Magellan™ platform?

Magellan™ is Gain Therapeutics' proprietary platform that uses AI and advanced algorithms to discover novel allosteric binding sites on disease-implicated proteins, leading to the identification of new therapeutic compounds.

What is unique about Gain Therapeutics' approach?

Gain Therapeutics' approach is unique because it focuses on allosteric modulation to restore or disrupt protein function, offering potential treatments for diseases that are currently untreatable or difficult to treat.

How does GT-02287 work?

GT-02287 works by modulating the function of the lysosomal enzyme glucocerebrosidase (GCase), which is impaired in GBA1 Parkinson's disease, helping to address the underlying cause of the disease.

Where can I find more information about Gain Therapeutics?

For more information about Gain Therapeutics, visit their website at GainTherapeutics.com or follow their updates on LinkedIn.

Gain Therapeutics, Inc.

Nasdaq:GANX

GANX Rankings

GANX Stock Data

34.73M
25.17M
6.76%
11.07%
2.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BETHESDA